Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

ThomasLD Oct. 4 at 4:56 PM

$GALT I believe $18B BO 🥇🥇🥇🤞🥂🥂🌙 because F4 has no competition and it is extremely high unmet need. 18/0.11925 ~ $150+ before short squeeze.

3 · Reply

Ledavee Oct. 4 at 3:29 PM

$GALT can’t stop thinking about warrants

0 · Reply

th3_fail_k1ng Oct. 4 at 3:19 PM

$GALT new article came out Mergetober the 1st so here's that: The Top Big Pharmas Have $1.2T in Stretch M&A Firepower Available - BioSpace https://share.google/sSkhNbKT8Y9XsaqKY

1 · Reply

LiquidThetaLEAPS Oct. 4 at 6:39 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $GALT Current Share Price: $4.33 Contracts: $GALT January 15, 2027 $5 Calls Scale in: $1.91- $2.33 Scale out: $2.97-$3.82 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

th3_fail_k1ng Oct. 4 at 4:53 AM

$GALT and the bearish as you want industry standard buyouts we should expect based off 3 billion in peak sales with the aforementioned approval. Sweet 😎💰💰💰💰🫡

4 · Reply

th3_fail_k1ng Oct. 4 at 4:51 AM

$GALT here you go the no cap, bleak as it gets fair shake reality of accelerated approval with no phase 3 and a post marketing trial. As bearish as possible delivered by a cold blooded machine (perplexity pro).......I like those odds 😆 I'm still calling it a sure thing imho

0 · Reply

thePistolPete Oct. 4 at 4:49 AM

$GALT 😂 the pumping on this board is unreal. I think it’s unlikely GALT ever brings a drug to market

1 · Reply

Gold70 Oct. 3 at 11:42 PM

$GALT if you believe it’s only short 9 million shares then you believe the market is not Manipulated. More likely double what they report. Shorts stand to loose 5 billion plus because there was no dilution back in 2019. They could loose more than total deal.

1 · Reply

Gold70 Oct. 3 at 11:24 PM

$GALT Question of the day. The music is slowing. Are we about to stop for alm the shorts. No dilution plans. Good luck shorties. https://www.youtube.com/watch?v=UOYi4NzxlhE

0 · Reply

ThomasLD Oct. 3 at 11:00 PM

$GALT This string of conversation mentioned with an average of 3 to 5B BO / 0.11925 ~ $25 to $41+. Why is it so low? Don’t you think this is the best drug on earth without competition? 3 to 5B BO is equivalent to around up to 9% ramp up sale by a big pharmaceutical company. Big D will laugh at them for that price. I say $18B BO.

3 · Reply

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

May 12, 2025, 8:00 AM EDT - 5 months ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Jan 10, 2025, 8:00 AM EST - 9 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 10:29 AM EST - 10 months ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 8:00 AM EST - 10 months ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Nov 18, 2024, 8:00 AM EST - 11 months ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 11 months ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 20, 2024, 8:11 PM EDT - 1 year ago

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 1 year ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 2 years ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GLTO

Sep 13, 2023, 5:22 PM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Apr 27, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Aug 15, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Jul 26, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

May 23, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

May 16, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

Apr 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Mar 31, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

ThomasLD Oct. 4 at 4:56 PM

$GALT I believe $18B BO 🥇🥇🥇🤞🥂🥂🌙 because F4 has no competition and it is extremely high unmet need. 18/0.11925 ~ $150+ before short squeeze.

3 · Reply

Ledavee Oct. 4 at 3:29 PM

$GALT can’t stop thinking about warrants

0 · Reply

th3_fail_k1ng Oct. 4 at 3:19 PM

$GALT new article came out Mergetober the 1st so here's that: The Top Big Pharmas Have $1.2T in Stretch M&A Firepower Available - BioSpace https://share.google/sSkhNbKT8Y9XsaqKY

1 · Reply

LiquidThetaLEAPS Oct. 4 at 6:39 AM

0 · Reply

th3_fail_k1ng Oct. 4 at 4:53 AM

$GALT and the bearish as you want industry standard buyouts we should expect based off 3 billion in peak sales with the aforementioned approval. Sweet 😎💰💰💰💰🫡

4 · Reply

th3_fail_k1ng Oct. 4 at 4:51 AM

0 · Reply

thePistolPete Oct. 4 at 4:49 AM

$GALT 😂 the pumping on this board is unreal. I think it’s unlikely GALT ever brings a drug to market

1 · Reply

Gold70 Oct. 3 at 11:42 PM

1 · Reply

Gold70 Oct. 3 at 11:24 PM

$GALT Question of the day. The music is slowing. Are we about to stop for alm the shorts. No dilution plans. Good luck shorties. https://www.youtube.com/watch?v=UOYi4NzxlhE

0 · Reply

ThomasLD Oct. 3 at 11:00 PM

3 · Reply

th3_fail_k1ng Oct. 3 at 10:22 PM

$GALT it will never cease to amaze me, people literally sit there and watch the crap the shorts put us through, stop loss raids, share price attacks, drag downs, all the other garbage they do to us, and they will come on here and brag about the pennies they make from share lending. Bro literally you are the reason the shorts have shares to do this to rest of us. At least have the decency not to brag about it. WTF 😒 I'm just going to put those guys on block my life is so much better not seeing them basically spitting in our faces.

3 · Reply

hardslog Oct. 3 at 8:44 PM

$GALT Cash rich Roche clearly drove a hard bargain with 89bio - eventually succeeding with $3.5b. The saga showed how a great asset can still go for far less than it's evident potential. It'll be interesting to see how we have gone with our hard bargaining and how much influence the independent valuation of belapectin will have on the final offer - if at all. Personally I'm hoping for something over $3B. Dream BO will be closer to $10B. It all depends on how desperate the buyer is imo. Massive market with no other competitors... let's hope we don't go for a song like 89.

5 · Reply

JollyAcorn2021 Oct. 3 at 7:32 PM

$GALT Anybody see any new information about our mystery German speaking negotiator who was liking our CMO's posts awhile back?

3 · Reply

Matolemeu Oct. 3 at 6:31 PM

$GALT another mortgage paid by Shorties borrowing shares. Thanks!

1 · Reply

ThomasLD Oct. 3 at 6:12 PM

$GALT If the 10x and big D (RU) warrants get issued by October 9th, something big is coming soon!🤞

2 · Reply

th3_fail_k1ng Oct. 3 at 6:11 PM

$GALT Hey guys, I've got to take a nap wake me up when we land at Lambo international airport I've got a connecting dolphin to Yachtsville that I don't want to miss.

0 · Reply

ThomasLD Oct. 3 at 5:45 PM

$GALT News (?) in October!!! PT $18B BO / 0.11925 ~ $150+ before short squeeze > $1000+ at any time before the end of the year.

2 · Reply

vikesfan6969 Oct. 3 at 5:41 PM

$GALT added Jan $5 calls here. Free money

2 · Reply

Bear_Police Oct. 3 at 5:09 PM

$GALT Might drop a bit just bought another 178 shares 😆

0 · Reply

johnhankowitz Oct. 3 at 5:01 PM

$GALT Can take off quick. Float is literally locked by insiders, longs & institutions. Conviction buy and hold for me…tick tock.

0 · Reply

Bear_Police Oct. 3 at 4:51 PM

$ABVE $GALT both badboys just waiting to explode! Octoberfest just heating up! One backed by a Billionaire prepping for a Buyout Aggressive by EOY $100+ TP The other backed by UAE billionaire royals ran by Peter of BlackRock Aggressive TP 90+ what else can you ask for? I might end up being the first millionaire in family 🙏🙏🙏

1 · Reply

calemay Oct. 3 at 4:06 PM

$GALT bought on the consolidation.....not sure if ill stick around.....it seems like they need a partner or offer.......lets see what happens

4 · Reply

Market Cap	272.26M
Revenue (ttm)	0.00
Net Income (ttm)	-47.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	213,300
Avg Vol	302,924
Day's Range	N/A - N/A
Shares Out	64.06M
Stochastic %K	26%
Beta	0.85
Analysts	Sell
Price Target	$6.00